Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Financial Performance and Strategy news
31 July 2026
Novo Nordisk: ZEUS phase 3 finds no MACE reduction with ziltivekimab
Ziltivekimab lowered free IL‑6 and hsCRP but did not reduce cardiovascular events; safety similar to placebo except for more serious infections; related trials continue with H1 2027 readouts.
31 July 2026
LyondellBasell Q2 2026 earnings
EBITDA $1.3bn ($2.1bn ex-items); net income $0.6bn ($1.4bn ex-items); completed European asset divestiture; $500m Cash Improvement Plan target by end‑2026.
31 July 2026
Moeve H1 2026: €1.2bn Clean CCS EBITDA; 69% of H1 capex to energy transition in Spain
Net income €458m, capex €605m and operating cash flow €762m; leverage fell to 1.2x; groundbreaking for 300 MW Andalusian Green Hydrogen Valley on Sept 17; Galp merger talks continue.
31 July 2026
FUCHS JV ALHAMRANI FUCHS PETROLEUM Yanbu plant severely damaged by fire
Fire on July 25 damaged production and filling units in Yanbu; operations suspended, no injuries. Customer supply to be maintained via alternative production and sourcing while reconstruction is planned.
31 July 2026
bp launches sale process for its North Sea business
Launching a process to market its North Sea business for potential sale, part of a portfolio review to focus capital on highest-value opportunities.
31 July 2026
OMV Petrom Group H1 2026 results
Clean CCS Operating Result 3 bn lei; net income 1.8 bn lei; CAPEX 3.7 bn lei; contribution to state budget 10.2 bn lei; Neptun Deep on track for first gas in 2027.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
31 July 2026
Umicore H1 2026 results
Adj. EBITDA +33% to €577m and margin 30.2%; revenues €1.9bn; Free Operating Cash Flow €295m; guidance upgraded to slightly above €1bn adj. EBITDA for FY2026.
31 July 2026
FUCHS posts 11% H1 sales growth to EUR 2,003m and raises EBIT outlook
EBIT rises 24% to EUR 260m; free cash flow before acquisitions EUR 61m; full takeover of Turkish JV in April 2026; Middle East conflict tightens base‑oil supply.
31 July 2026
OMV Q2 2026: Clean CCS operating result €1,706m
Strong cash flow and low leverage; all segments profitable. Chemicals lifted by Borouge International closing and higher olefin/polyolefin prices.
31 July 2026
Clariant Q2 2026: margins improve and Amsterdam court dismisses Shell ethylene claim
Q2 comparable sales roughly flat; EBITDA margin up 80bp; performance-savings target raised to CHF100m; Amsterdam court dismissed Shell and Stichting Ethylene Claims suits.
31 July 2026
Holcim: H1 recurring EBIT +11.5% organically, guidance upgraded
Net sales +5.2% organic H1; recurring EBIT margin 18.1%; closed Xella and Cementos Pacasmayo; FY2026 guidance raised to ~5% sales and ~10% recurring EBIT growth.
31 July 2026
MCG Group Q1 consolidated results (FY Mar 2027)
Sales rose 14% to ¥1,004.2bn; core operating income doubled to ¥114.1bn. Semiconductor demand, higher prices, FX and Middle East-driven naphtha effects boosted performance.
31 July 2026
Borouge Plc delivers 23% QoQ net profit rise despite Ruwais incident
Restored full production after 5 April incident; shipped all available volumes plus inventory; realised prices rose 53% QoQ; margins squeezed by higher logistics and propylene costs.
30 July 2026
Huntsman Q2 2026 results and Olin merger update
Q2 net loss $6M, adjusted EBITDA $120M; free cash flow used $90M; signed all‑stock merger with Olin; stockholder vote Aug 25, 2026.
30 July 2026
TechnipFMC Q2 2026 results
Revenue $2.76bn; net income $363m; Subsea inbound $2.5bn; cash from operations $548m and free cash flow $488m; $440m returned to shareholders.
30 July 2026
Takeda Q1 FY2026 results and ORZEYFUL China approval
Solid quarter: revenue +10.2% AER; adjusted free cash flow JPY 68.6bn; launch prep for ORZEYFUL, rusfertide and zasocitinib; FY2026 outlook unchanged.
30 July 2026
Arkema Q2 2026 results
EBITDA +7.4% YoY to €391m and margin 16.1%; organic sales +3.2%; raw-material cost spike prompted pricing moves; FY‑26 EBITDA guidance slightly above last year at constant FX.
30 July 2026
Heidelberg Materials reports Q2 revenue €6.04bn and narrows 2026 RCO range
Revenue rose 6% to €6,044m and RCO to €1,086m. Strategic acquisitions in North America and Turkey; new 1.25 Mt kiln in France and Padeswood CCS on schedule.
30 July 2026
Vopak H1 2026 results: raises FY outlook and declares EUR 0.72 interim dividend
Raised FY2026 proportional EBITDA and operating free cash flow guidance; first semi‑annual interim dividend of EUR 0.72; major growth and BESS investments progressing.
30 July 2026
Symrise H1 2026: €2.54bn sales as Q2 organic growth accelerates
Organic growth accelerated to 4.5% in Q2; H1 sales €2.54bn, adjusted EBITDA margin 21.8%, offer for Floral Concept and ONE SYM transformation accelerated.
30 July 2026
WACKER Q2 2026 results — PACE savings and pension effect boost earnings
Q2 sales €1.52bn; EBITDA €211m aided by cost cuts and a €36.7m pension revaluation; net income includes €243m from Siltronic sale; full‑year guidance adjusted.
30 July 2026
Technip Energies H1 2026: €12.7bn order intake and €25bn backlog
Order intake €12.7bn raised backlog to €25bn; H1 revenue €3.7bn and EBITDA €212m after provisions; Project Delivery margin guidance reduced for 2026.
30 July 2026
MAIRE: H1 2026 results — €3.7bn revenues, strong order intake and M&A in Nextchem
Revenues +6.9% to €3.68bn; EBITDA +14.7% to €266.2m; H1 order intake €7.2bn, backlog €16.3bn; Nextchem buys Ballestra and 70% of ETEK.
29 July 2026
SABIC Q2 2026 revenue $6.62bn; earnings fall
Q2 sales fell 5% Q-o-Q; adjusted EBITDA SAR 3.38bn; H1 dividend SAR 3.3bn; Fujian complex start-up expected Q4 2026.
29 July 2026
Johnson & Johnson completes $1 billion acquisition of Firefly Bio
Adds Firelink™ degrader antibody conjugate platform to target pan‑KRAS and other hard‑to‑treat solid tumors; transaction carries near‑term R&D charge and EPS dilution.
29 July 2026
Johnson & Johnson partners with Sail Biomedicines on in vivo CAR‑T with $2.58B acquisition option
Advance lead in vivo CAR‑T program to reset the immune system for immune‑mediated disease; $785M initial funding, $140M milestones, and a $2.58B acquisition option.
29 July 2026
BASF reports stronger Q2 results, advances restructuring and portfolio moves
Earnings rose across most segments on stronger prices and volumes; Q2 sales €17.2bn and EBITDA before special items €2.4bn; full-year EBITDA guidance lifted to €6.9–7.7bn.
28 July 2026
Ercros H1 2026 results and approved delisting
Net loss €3.9m in H1 2026 despite €22.7m adjusted EBITDA; liquidity €75m; delisting approved with Bondalti Iberica tender at €3.505/share.
28 July 2026
GSK Q2: strong core results, R&D acceleration and 20+ Phase III starts in 2026
Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
28 July 2026
Croda H1 2026 results: £880.5m sales and margin progress from transformation
Group organic sales +4.6% in H1; adjusted operating profit £155.8m; free cash flow up 36.8%; FY26 guidance unchanged with 3–6% organic range.
Next →
